Spotlight Pathology

Spotlight Pathology, a spinout from the University of Manchester, has secured a new investment of £1.4m to accelerate the commercial rollout of its AI cancer diagnostics product. This funding is critical for the company to transition its primary focus from technology development to supporting its products in clinical use, with initial deployments expected in NHS sites later this year.

Summary of transaction details:

• Value: £1.4m
• Sector: Health Technology, AI Cancer Diagnostics
• Advisor: None mentioned
• Key Entities: Target: Spotlight Pathology; Co-Lead Investors: Liverpool City Region Seed Fund, UKI2S; Additional Investors: Deepbridge, Lyva Labs, EHE Ventures, River Capital
• Location: Sci-Tech Daresbury (Target company base)

Note: This investment is strategic for Spotlight Pathology as it moves beyond the development phase towards commercialization and clinical application of its AI lymphoma diagnostic device, addressing a critical need in healthcare through advanced technology.